Profound Medical Corp. 8-K

What Happened
Profound Medical Corp. announced on January 6, 2026 (via an 8-K, Item 7.01 Regulation FD Disclosure) that The Johns Hopkins Hospital has treated its first non-clinical-trial prostate cancer patient using the Company’s TULSA‑PRO® system. The company furnished a press release describing the event as Exhibit 99.1 to the Form 8-K.

Key Details

• Filing date: January 6, 2026; disclosure made under Item 7.01 (Regulation FD Disclosure).
• Event: The Johns Hopkins Hospital performed its first non‑clinical‑trial prostate cancer treatment with TULSA‑PRO.
• Exhibit: Press release dated January 6, 2026 was furnished as Exhibit 99.1 to the 8-K.
• The Form 8-K was signed by Chief Financial Officer Rashed Dewan.

Why It Matters
This 8-K documents real‑world use of Profound’s TULSA‑PRO system at a leading academic medical center and was considered material enough to disclose under Regulation FD. The filing itself contains no earnings, revenue figures, or other financial results; investors should view this as a clinical/commercial adoption update (not a financial report) and watch for follow‑up releases or filings that quantify any impact on sales, revenue, or broader commercial rollout.